Clinical development, trial recruitment and regulatory approval answer different questions. This reference pairs selected registry records with published evidence, preserving their dates and limits.
Selected source-checked trials
Registry status and published results are shown separately. Treatment averages across different studies are not a ranking or a prediction for an individual.
TRIUMPH-1
NCT05929066 · Retatrutide profile
- Sponsor
- Eli Lilly and Company
- Phase
- Phase 3
- Registry status
- completed
- Registry enrollment
- 2335 (actual)
- Published analysis population
- 2339
- Analysis time point
- 80 weeks
- Population
- Adults with obesity, or overweight with weight-related complications, without diabetes. Exact eligibility differs by trial; consult the linked protocol.
- Registry checked
- 2026-10-03
Registry actual enrollment 2335 differs from 2339 randomized in the paper; the reason was not established from these sources.
| Historical trial arm | Mean change from baseline |
|---|---|
| retatrutide 4 mg trial arm | -17.6% |
| retatrutide 9 mg trial arm | -23.7% |
| retatrutide 12 mg trial arm | -25.0% |
| placebo | -3.9% |
Negative values indicate a decrease from baseline. Arm dose labels describe the research protocol, not a dosing recommendation.
Original study abstract · Full registry record
The original abstract and registry were checked; full texts and supplements were not independently reviewed. Confidence intervals absent from this record must not be inferred. These selected results do not describe every safety finding or subgroup.
REDEFINE 1
NCT05567796 · Cagrisema profile
- Sponsor
- Novo Nordisk A/S
- Phase
- Phase 3
- Registry status
- active not recruiting
- Registry enrollment
- 3400 (estimated)
- Published analysis population
- 3417
- Analysis time point
- 68 weeks
- Population
- Adults with obesity, or overweight with weight-related complications, without diabetes. Exact eligibility differs by trial; consult the linked protocol.
- Registry checked
- 2026-10-03
Registry estimated enrollment 3400 is a planning value; the published randomized population is 3417.
| Historical trial arm | Mean change from baseline |
|---|---|
| cagrilintide 2.4 mg plus semaglutide 2.4 mg trial arm | -20.4% |
| placebo | -3.0% |
Negative values indicate a decrease from baseline. Arm dose labels describe the research protocol, not a dosing recommendation.
Original study abstract · Full registry record
The original abstract and registry were checked; full texts and supplements were not independently reviewed. Confidence intervals absent from this record must not be inferred. These selected results do not describe every safety finding or subgroup.
ATTAIN-1
NCT05869903 · Orforglipron profile
- Sponsor
- Eli Lilly and Company
- Phase
- Phase 3
- Registry status
- active not recruiting
- Registry enrollment
- 3127 (actual)
- Published analysis population
- 3127
- Analysis time point
- 72 weeks
- Population
- Adults with obesity, or overweight with weight-related complications, without diabetes. Exact eligibility differs by trial; consult the linked protocol.
- Registry checked
- 2026-10-03
Registry actual enrollment and published randomized population both equal 3127.
| Historical trial arm | Mean change from baseline |
|---|---|
| orforglipron 6 mg trial arm | -7.5% |
| orforglipron 12 mg trial arm | -8.4% |
| orforglipron 36 mg trial arm | -11.2% |
| placebo | -2.1% |
Negative values indicate a decrease from baseline. Arm dose labels describe the research protocol, not a dosing recommendation.
Original study abstract · Full registry record
The original abstract and registry were checked; full texts and supplements were not independently reviewed. Confidence intervals absent from this record must not be inferred. These selected results do not describe every safety finding or subgroup.
SYNCHRONIZE-1
NCT06066515 · Survodutide profile
- Sponsor
- Boehringer Ingelheim
- Phase
- Phase 3
- Registry status
- completed
- Registry enrollment
- 726 (actual)
- Published analysis population
- 725
- Analysis time point
- 76 weeks
- Population
- Adults with obesity, or overweight with weight-related complications, without diabetes. Exact eligibility differs by trial; consult the linked protocol.
- Registry checked
- 2026-10-03
Registry actual enrollment is 726; the paper abstract reports outcomes among 725 participants. This dataset retains both denominators without assuming why they differ.
| Historical trial arm | Mean change from baseline |
|---|---|
| survodutide up to 3.6 mg trial arm | -12.2% |
| survodutide up to 6.0 mg trial arm | -13.0% |
| placebo | -5.4% |
Negative values indicate a decrease from baseline. Arm dose labels describe the research protocol, not a dosing recommendation.
Original study abstract · Full registry record
The original abstract and registry were checked; full texts and supplements were not independently reviewed. Confidence intervals absent from this record must not be inferred. These selected results do not describe every safety finding or subgroup.
STEP 1
NCT03548935 · Semaglutide profile
- Sponsor
- Novo Nordisk A/S
- Phase
- Phase 3
- Registry status
- completed
- Registry enrollment
- 1961 (actual)
- Published analysis population
- 1961
- Analysis time point
- 68 weeks
- Population
- Adults with obesity, or overweight with weight-related complications, without diabetes. Exact eligibility differs by trial; consult the linked protocol.
- Registry checked
- 2026-10-03
Registry actual enrollment and published enrolled population both equal 1961.
| Historical trial arm | Mean change from baseline |
|---|---|
| semaglutide 2.4 mg trial arm | -14.9% |
| placebo | -2.4% |
Negative values indicate a decrease from baseline. Arm dose labels describe the research protocol, not a dosing recommendation.
Original study abstract · Full registry record
The original abstract and registry were checked; full texts and supplements were not independently reviewed. Confidence intervals absent from this record must not be inferred. These selected results do not describe every safety finding or subgroup.
SURMOUNT-1
NCT04184622 · Tirzepatide profile
- Sponsor
- Eli Lilly and Company
- Phase
- Phase 3
- Registry status
- completed
- Registry enrollment
- 2539 (actual)
- Published analysis population
- 2539
- Analysis time point
- 72 weeks
- Population
- Adults with obesity, or overweight with weight-related complications, without diabetes. Exact eligibility differs by trial; consult the linked protocol.
- Registry checked
- 2026-10-03
Registry actual enrollment and published randomized population both equal 2539.
| Historical trial arm | Mean change from baseline |
|---|---|
| tirzepatide 5 mg trial arm | -15.0% |
| tirzepatide 10 mg trial arm | -19.5% |
| tirzepatide 15 mg trial arm | -20.9% |
| placebo | -3.1% |
Negative values indicate a decrease from baseline. Arm dose labels describe the research protocol, not a dosing recommendation.
Original study abstract · Full registry record
The original abstract and registry were checked; full texts and supplements were not independently reviewed. Confidence intervals absent from this record must not be inferred. These selected results do not describe every safety finding or subgroup.
How to read this tracker
A trial may have published results while its registry remains active. A registry enrollment field can differ from the number randomized or included in a publication analysis. Both are shown when available. A trial phase is not a marketing authorization.
Published weight changes retain duration, population, intervention, comparator and analysis method. These are not comparable treatment rankings and do not predict an individual response. Registry updates can lag the actual research process.
Methods and updates
Our source hierarchy starts with trial registries, regulatory records and peer-reviewed papers. Manufacturer announcements are identified separately. Data are selected and checked against the linked documents; proposed automated registry changes require an evidence check before the public record changes. How we check evidence.
Use the percentage calculator for measurement arithmetic and the Drug Tracker for medicine profiles. Questions about a record can be sent through Contact. This tracker is educational and cannot guide self-prescribing or individual treatment.